Johnson & Johnson (JNJ.US) has obtained positive key results from two Phase III studies of its oral IL-23R antagonist.
Johnson & Johnson (JNJ.US) announced that the oral IL-23R antagonist Icotrokinra (JNJ-2113) has obtained positive key results in the Phase III ICONIC-LEAD study for the treatment of plaque psoriasis (PsO).
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Express News | J&J: He Phase 3 Iconic-Psa Program Which Will Investigate Icotrokinra in Psoriatic Arthritis Will Be Initiated in the Beginning of 2025
Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With...
Express News | Johnson & Johnson - 74% of Patients Achieved Clear or Almost Clear Skin at Week 24
Express News | Johnson & Johnson - Icotrokinra Meets Co-Primary Endpoints in Phase 3 Study